Nature Communications-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2228483, encodeId=842c22284832f, content=偏重的研究方向：医学;综合性期刊 经验分享：12天了，还在manuscript under consideration，编辑处理是真的慢🙃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd35613068, createdName=ms1000000741572856, createdTime=Mon Sep 30 00:24:29 CST 2024, time=2024-09-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=855, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2291254, encodeId=207222912548f, content=偏重的研究方向：医学;分子生物学 经验分享：之前投过一篇，外审两个多月杯具。11月20号又投了另一篇，11月27号muc，希望给个机会送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9349755523, createdName=ms4000002010943622, createdTime=Sun Nov 30 22:49:46 CST 2025, time=2025-11-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2223835, encodeId=c62622238351c, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：分子生物学 经验分享：从投稿到正式接受历时一年，经过三轮修改，每轮审稿周期都不超过一个月，最终有了好的结果。人生第一篇NC！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16c85167147, createdName=146cbb29m02暂无昵称, createdTime=Tue Sep 03 13:13:35 CST 2024, time=2024-09-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2285207, encodeId=c855228520eed, content=nature communication为什么第一个审稿人审稿一结束，就把意见发给我了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 10:45:01 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286693, encodeId=91272286693af, content=各位院士，请问nc的外审通过率有多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b49839896, createdName=ms9000001395868499, createdTime=Wed Oct 29 09:15:14 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285205, encodeId=8d28228520562, content=偏重的研究方向：缺血再灌注损伤;肠黏膜 经验分享：我目前有两个审稿人，第一个昨天完成审稿，编辑居然把第一个审稿人的意见发给我了，看邮件的意思像拒稿也像大修，审稿人的最后一句话：Taken together I cannot recommend the manuscript for publication in its present form.大家有遇到这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 09:55:05 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2224058, encodeId=2d6b22240584c, content=有大佬知道Review Complete后还要多久编辑才返回结果吗？ Stage Start Date Manuscript under consideration 22nd August 24 Review Complete 22nd August 24 All Reviewers Assigned 5th August 24 Manuscript under consideration 4th August 24 Contacting Potential Reviewers 4th August 24 Manuscript under consideration 30th July 24 Editor Assigned 30th July 24 Manuscript submitted 29th July 24 Submission in process 29th July 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a8426823, createdName=ms9000001478887667, createdTime=Wed Sep 04 17:45:14 CST 2024, time=2024-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2284421, encodeId=6812228442158, content=投稿命中率:25.0 偏重的研究方向：分子生物学;血液 经验分享：实验室同时投了两篇NC，两篇都是投大子刊被拒要求转NC的，结果大家觉得质量更高的那一篇反而被NC编辑直接拒了，另一篇技术含量低一些但带领域交叉的一篇送审修回了，直接脑子懵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b049736141, createdName=ms3000001475237117, createdTime=Sat Oct 11 17:03:48 CST 2025, time=2025-10-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1240708, encodeId=34761240e08c3, content=有从nature metabolism transfer过来NC的吗? 送审机会大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VsrhoYCAOiaTrrwt0HqSsGYQYegxVBadSem5S9wJnOugf5N8INwXDaicZTRzeAIp3Qiae0Qabf6AEQzTibZkyLrNJA/132, createdBy=9f7e2217563, createdName=good123, createdTime=Wed Aug 24 14:00:17 CST 2022, time=2022-08-24, status=1, ipAttribution=)]

2024-09-30 ms1000000741572856 来自广东省

偏重的研究方向：医学;综合性期刊
经验分享：12天了，还在manuscript under consideration，编辑处理是真的慢🙃

327 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2228483, encodeId=842c22284832f, content=偏重的研究方向：医学;综合性期刊 经验分享：12天了，还在manuscript under consideration，编辑处理是真的慢🙃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd35613068, createdName=ms1000000741572856, createdTime=Mon Sep 30 00:24:29 CST 2024, time=2024-09-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=855, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2291254, encodeId=207222912548f, content=偏重的研究方向：医学;分子生物学 经验分享：之前投过一篇，外审两个多月杯具。11月20号又投了另一篇，11月27号muc，希望给个机会送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9349755523, createdName=ms4000002010943622, createdTime=Sun Nov 30 22:49:46 CST 2025, time=2025-11-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2223835, encodeId=c62622238351c, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：分子生物学 经验分享：从投稿到正式接受历时一年，经过三轮修改，每轮审稿周期都不超过一个月，最终有了好的结果。人生第一篇NC！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16c85167147, createdName=146cbb29m02暂无昵称, createdTime=Tue Sep 03 13:13:35 CST 2024, time=2024-09-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2285207, encodeId=c855228520eed, content=nature communication为什么第一个审稿人审稿一结束，就把意见发给我了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 10:45:01 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286693, encodeId=91272286693af, content=各位院士，请问nc的外审通过率有多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b49839896, createdName=ms9000001395868499, createdTime=Wed Oct 29 09:15:14 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285205, encodeId=8d28228520562, content=偏重的研究方向：缺血再灌注损伤;肠黏膜 经验分享：我目前有两个审稿人，第一个昨天完成审稿，编辑居然把第一个审稿人的意见发给我了，看邮件的意思像拒稿也像大修，审稿人的最后一句话：Taken together I cannot recommend the manuscript for publication in its present form.大家有遇到这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 09:55:05 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2224058, encodeId=2d6b22240584c, content=有大佬知道Review Complete后还要多久编辑才返回结果吗？ Stage Start Date Manuscript under consideration 22nd August 24 Review Complete 22nd August 24 All Reviewers Assigned 5th August 24 Manuscript under consideration 4th August 24 Contacting Potential Reviewers 4th August 24 Manuscript under consideration 30th July 24 Editor Assigned 30th July 24 Manuscript submitted 29th July 24 Submission in process 29th July 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a8426823, createdName=ms9000001478887667, createdTime=Wed Sep 04 17:45:14 CST 2024, time=2024-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2284421, encodeId=6812228442158, content=投稿命中率:25.0 偏重的研究方向：分子生物学;血液 经验分享：实验室同时投了两篇NC，两篇都是投大子刊被拒要求转NC的，结果大家觉得质量更高的那一篇反而被NC编辑直接拒了，另一篇技术含量低一些但带领域交叉的一篇送审修回了，直接脑子懵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b049736141, createdName=ms3000001475237117, createdTime=Sat Oct 11 17:03:48 CST 2025, time=2025-10-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1240708, encodeId=34761240e08c3, content=有从nature metabolism transfer过来NC的吗? 送审机会大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VsrhoYCAOiaTrrwt0HqSsGYQYegxVBadSem5S9wJnOugf5N8INwXDaicZTRzeAIp3Qiae0Qabf6AEQzTibZkyLrNJA/132, createdBy=9f7e2217563, createdName=good123, createdTime=Wed Aug 24 14:00:17 CST 2022, time=2022-08-24, status=1, ipAttribution=)]

2022-01-28 hezhixin

偏重的研究方向：综合学科
经验分享：已经under consideration9天了，还有希望吗？？兄弟们？

855 9 举报

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2228483, encodeId=842c22284832f, content=偏重的研究方向：医学;综合性期刊 经验分享：12天了，还在manuscript under consideration，编辑处理是真的慢🙃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd35613068, createdName=ms1000000741572856, createdTime=Mon Sep 30 00:24:29 CST 2024, time=2024-09-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=855, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2291254, encodeId=207222912548f, content=偏重的研究方向：医学;分子生物学 经验分享：之前投过一篇，外审两个多月杯具。11月20号又投了另一篇，11月27号muc，希望给个机会送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9349755523, createdName=ms4000002010943622, createdTime=Sun Nov 30 22:49:46 CST 2025, time=2025-11-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2223835, encodeId=c62622238351c, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：分子生物学 经验分享：从投稿到正式接受历时一年，经过三轮修改，每轮审稿周期都不超过一个月，最终有了好的结果。人生第一篇NC！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16c85167147, createdName=146cbb29m02暂无昵称, createdTime=Tue Sep 03 13:13:35 CST 2024, time=2024-09-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2285207, encodeId=c855228520eed, content=nature communication为什么第一个审稿人审稿一结束，就把意见发给我了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 10:45:01 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286693, encodeId=91272286693af, content=各位院士，请问nc的外审通过率有多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b49839896, createdName=ms9000001395868499, createdTime=Wed Oct 29 09:15:14 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285205, encodeId=8d28228520562, content=偏重的研究方向：缺血再灌注损伤;肠黏膜 经验分享：我目前有两个审稿人，第一个昨天完成审稿，编辑居然把第一个审稿人的意见发给我了，看邮件的意思像拒稿也像大修，审稿人的最后一句话：Taken together I cannot recommend the manuscript for publication in its present form.大家有遇到这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 09:55:05 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2224058, encodeId=2d6b22240584c, content=有大佬知道Review Complete后还要多久编辑才返回结果吗？ Stage Start Date Manuscript under consideration 22nd August 24 Review Complete 22nd August 24 All Reviewers Assigned 5th August 24 Manuscript under consideration 4th August 24 Contacting Potential Reviewers 4th August 24 Manuscript under consideration 30th July 24 Editor Assigned 30th July 24 Manuscript submitted 29th July 24 Submission in process 29th July 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a8426823, createdName=ms9000001478887667, createdTime=Wed Sep 04 17:45:14 CST 2024, time=2024-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2284421, encodeId=6812228442158, content=投稿命中率:25.0 偏重的研究方向：分子生物学;血液 经验分享：实验室同时投了两篇NC，两篇都是投大子刊被拒要求转NC的，结果大家觉得质量更高的那一篇反而被NC编辑直接拒了，另一篇技术含量低一些但带领域交叉的一篇送审修回了，直接脑子懵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b049736141, createdName=ms3000001475237117, createdTime=Sat Oct 11 17:03:48 CST 2025, time=2025-10-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1240708, encodeId=34761240e08c3, content=有从nature metabolism transfer过来NC的吗? 送审机会大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VsrhoYCAOiaTrrwt0HqSsGYQYegxVBadSem5S9wJnOugf5N8INwXDaicZTRzeAIp3Qiae0Qabf6AEQzTibZkyLrNJA/132, createdBy=9f7e2217563, createdName=good123, createdTime=Wed Aug 24 14:00:17 CST 2022, time=2022-08-24, status=1, ipAttribution=)]

2025-11-30 ms4000002010943622 来自北京

偏重的研究方向：医学;分子生物学
经验分享：之前投过一篇，外审两个多月杯具。11月20号又投了另一篇，11月27号muc，希望给个机会送审

185 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2228483, encodeId=842c22284832f, content=偏重的研究方向：医学;综合性期刊 经验分享：12天了，还在manuscript under consideration，编辑处理是真的慢🙃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd35613068, createdName=ms1000000741572856, createdTime=Mon Sep 30 00:24:29 CST 2024, time=2024-09-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=855, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2291254, encodeId=207222912548f, content=偏重的研究方向：医学;分子生物学 经验分享：之前投过一篇，外审两个多月杯具。11月20号又投了另一篇，11月27号muc，希望给个机会送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9349755523, createdName=ms4000002010943622, createdTime=Sun Nov 30 22:49:46 CST 2025, time=2025-11-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2223835, encodeId=c62622238351c, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：分子生物学 经验分享：从投稿到正式接受历时一年，经过三轮修改，每轮审稿周期都不超过一个月，最终有了好的结果。人生第一篇NC！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16c85167147, createdName=146cbb29m02暂无昵称, createdTime=Tue Sep 03 13:13:35 CST 2024, time=2024-09-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2285207, encodeId=c855228520eed, content=nature communication为什么第一个审稿人审稿一结束，就把意见发给我了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 10:45:01 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286693, encodeId=91272286693af, content=各位院士，请问nc的外审通过率有多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b49839896, createdName=ms9000001395868499, createdTime=Wed Oct 29 09:15:14 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285205, encodeId=8d28228520562, content=偏重的研究方向：缺血再灌注损伤;肠黏膜 经验分享：我目前有两个审稿人，第一个昨天完成审稿，编辑居然把第一个审稿人的意见发给我了，看邮件的意思像拒稿也像大修，审稿人的最后一句话：Taken together I cannot recommend the manuscript for publication in its present form.大家有遇到这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 09:55:05 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2224058, encodeId=2d6b22240584c, content=有大佬知道Review Complete后还要多久编辑才返回结果吗？ Stage Start Date Manuscript under consideration 22nd August 24 Review Complete 22nd August 24 All Reviewers Assigned 5th August 24 Manuscript under consideration 4th August 24 Contacting Potential Reviewers 4th August 24 Manuscript under consideration 30th July 24 Editor Assigned 30th July 24 Manuscript submitted 29th July 24 Submission in process 29th July 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a8426823, createdName=ms9000001478887667, createdTime=Wed Sep 04 17:45:14 CST 2024, time=2024-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2284421, encodeId=6812228442158, content=投稿命中率:25.0 偏重的研究方向：分子生物学;血液 经验分享：实验室同时投了两篇NC，两篇都是投大子刊被拒要求转NC的，结果大家觉得质量更高的那一篇反而被NC编辑直接拒了，另一篇技术含量低一些但带领域交叉的一篇送审修回了，直接脑子懵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b049736141, createdName=ms3000001475237117, createdTime=Sat Oct 11 17:03:48 CST 2025, time=2025-10-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1240708, encodeId=34761240e08c3, content=有从nature metabolism transfer过来NC的吗? 送审机会大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VsrhoYCAOiaTrrwt0HqSsGYQYegxVBadSem5S9wJnOugf5N8INwXDaicZTRzeAIp3Qiae0Qabf6AEQzTibZkyLrNJA/132, createdBy=9f7e2217563, createdName=good123, createdTime=Wed Aug 24 14:00:17 CST 2022, time=2022-08-24, status=1, ipAttribution=)]

2024-09-03 146cbb29m02暂无昵称来自山东省

审稿速度:1.0 | 投稿命中率:5.0
偏重的研究方向：分子生物学
经验分享：从投稿到正式接受历时一年，经过三轮修改，每轮审稿周期都不超过一个月，最终有了好的结果。人生第一篇NC！

637 3 举报

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2228483, encodeId=842c22284832f, content=偏重的研究方向：医学;综合性期刊 经验分享：12天了，还在manuscript under consideration，编辑处理是真的慢🙃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd35613068, createdName=ms1000000741572856, createdTime=Mon Sep 30 00:24:29 CST 2024, time=2024-09-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=855, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2291254, encodeId=207222912548f, content=偏重的研究方向：医学;分子生物学 经验分享：之前投过一篇，外审两个多月杯具。11月20号又投了另一篇，11月27号muc，希望给个机会送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9349755523, createdName=ms4000002010943622, createdTime=Sun Nov 30 22:49:46 CST 2025, time=2025-11-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2223835, encodeId=c62622238351c, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：分子生物学 经验分享：从投稿到正式接受历时一年，经过三轮修改，每轮审稿周期都不超过一个月，最终有了好的结果。人生第一篇NC！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16c85167147, createdName=146cbb29m02暂无昵称, createdTime=Tue Sep 03 13:13:35 CST 2024, time=2024-09-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2285207, encodeId=c855228520eed, content=nature communication为什么第一个审稿人审稿一结束，就把意见发给我了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 10:45:01 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286693, encodeId=91272286693af, content=各位院士，请问nc的外审通过率有多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b49839896, createdName=ms9000001395868499, createdTime=Wed Oct 29 09:15:14 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285205, encodeId=8d28228520562, content=偏重的研究方向：缺血再灌注损伤;肠黏膜 经验分享：我目前有两个审稿人，第一个昨天完成审稿，编辑居然把第一个审稿人的意见发给我了，看邮件的意思像拒稿也像大修，审稿人的最后一句话：Taken together I cannot recommend the manuscript for publication in its present form.大家有遇到这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 09:55:05 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2224058, encodeId=2d6b22240584c, content=有大佬知道Review Complete后还要多久编辑才返回结果吗？ Stage Start Date Manuscript under consideration 22nd August 24 Review Complete 22nd August 24 All Reviewers Assigned 5th August 24 Manuscript under consideration 4th August 24 Contacting Potential Reviewers 4th August 24 Manuscript under consideration 30th July 24 Editor Assigned 30th July 24 Manuscript submitted 29th July 24 Submission in process 29th July 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a8426823, createdName=ms9000001478887667, createdTime=Wed Sep 04 17:45:14 CST 2024, time=2024-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2284421, encodeId=6812228442158, content=投稿命中率:25.0 偏重的研究方向：分子生物学;血液 经验分享：实验室同时投了两篇NC，两篇都是投大子刊被拒要求转NC的，结果大家觉得质量更高的那一篇反而被NC编辑直接拒了，另一篇技术含量低一些但带领域交叉的一篇送审修回了，直接脑子懵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b049736141, createdName=ms3000001475237117, createdTime=Sat Oct 11 17:03:48 CST 2025, time=2025-10-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1240708, encodeId=34761240e08c3, content=有从nature metabolism transfer过来NC的吗? 送审机会大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VsrhoYCAOiaTrrwt0HqSsGYQYegxVBadSem5S9wJnOugf5N8INwXDaicZTRzeAIp3Qiae0Qabf6AEQzTibZkyLrNJA/132, createdBy=9f7e2217563, createdName=good123, createdTime=Wed Aug 24 14:00:17 CST 2022, time=2022-08-24, status=1, ipAttribution=)]

2025-10-18 sunyong_97 来自湖北省

nature communication为什么第一个审稿人审稿一结束，就把意见发给我了呢？

231 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2228483, encodeId=842c22284832f, content=偏重的研究方向：医学;综合性期刊 经验分享：12天了，还在manuscript under consideration，编辑处理是真的慢🙃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd35613068, createdName=ms1000000741572856, createdTime=Mon Sep 30 00:24:29 CST 2024, time=2024-09-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=855, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2291254, encodeId=207222912548f, content=偏重的研究方向：医学;分子生物学 经验分享：之前投过一篇，外审两个多月杯具。11月20号又投了另一篇，11月27号muc，希望给个机会送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9349755523, createdName=ms4000002010943622, createdTime=Sun Nov 30 22:49:46 CST 2025, time=2025-11-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2223835, encodeId=c62622238351c, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：分子生物学 经验分享：从投稿到正式接受历时一年，经过三轮修改，每轮审稿周期都不超过一个月，最终有了好的结果。人生第一篇NC！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16c85167147, createdName=146cbb29m02暂无昵称, createdTime=Tue Sep 03 13:13:35 CST 2024, time=2024-09-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2285207, encodeId=c855228520eed, content=nature communication为什么第一个审稿人审稿一结束，就把意见发给我了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 10:45:01 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286693, encodeId=91272286693af, content=各位院士，请问nc的外审通过率有多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b49839896, createdName=ms9000001395868499, createdTime=Wed Oct 29 09:15:14 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285205, encodeId=8d28228520562, content=偏重的研究方向：缺血再灌注损伤;肠黏膜 经验分享：我目前有两个审稿人，第一个昨天完成审稿，编辑居然把第一个审稿人的意见发给我了，看邮件的意思像拒稿也像大修，审稿人的最后一句话：Taken together I cannot recommend the manuscript for publication in its present form.大家有遇到这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 09:55:05 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2224058, encodeId=2d6b22240584c, content=有大佬知道Review Complete后还要多久编辑才返回结果吗？ Stage Start Date Manuscript under consideration 22nd August 24 Review Complete 22nd August 24 All Reviewers Assigned 5th August 24 Manuscript under consideration 4th August 24 Contacting Potential Reviewers 4th August 24 Manuscript under consideration 30th July 24 Editor Assigned 30th July 24 Manuscript submitted 29th July 24 Submission in process 29th July 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a8426823, createdName=ms9000001478887667, createdTime=Wed Sep 04 17:45:14 CST 2024, time=2024-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2284421, encodeId=6812228442158, content=投稿命中率:25.0 偏重的研究方向：分子生物学;血液 经验分享：实验室同时投了两篇NC，两篇都是投大子刊被拒要求转NC的，结果大家觉得质量更高的那一篇反而被NC编辑直接拒了，另一篇技术含量低一些但带领域交叉的一篇送审修回了，直接脑子懵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b049736141, createdName=ms3000001475237117, createdTime=Sat Oct 11 17:03:48 CST 2025, time=2025-10-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1240708, encodeId=34761240e08c3, content=有从nature metabolism transfer过来NC的吗? 送审机会大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VsrhoYCAOiaTrrwt0HqSsGYQYegxVBadSem5S9wJnOugf5N8INwXDaicZTRzeAIp3Qiae0Qabf6AEQzTibZkyLrNJA/132, createdBy=9f7e2217563, createdName=good123, createdTime=Wed Aug 24 14:00:17 CST 2022, time=2022-08-24, status=1, ipAttribution=)]

2025-10-29 ms9000001395868499 来自广东省

各位院士，请问nc的外审通过率有多少？

199 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2228483, encodeId=842c22284832f, content=偏重的研究方向：医学;综合性期刊 经验分享：12天了，还在manuscript under consideration，编辑处理是真的慢🙃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd35613068, createdName=ms1000000741572856, createdTime=Mon Sep 30 00:24:29 CST 2024, time=2024-09-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=855, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2291254, encodeId=207222912548f, content=偏重的研究方向：医学;分子生物学 经验分享：之前投过一篇，外审两个多月杯具。11月20号又投了另一篇，11月27号muc，希望给个机会送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9349755523, createdName=ms4000002010943622, createdTime=Sun Nov 30 22:49:46 CST 2025, time=2025-11-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2223835, encodeId=c62622238351c, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：分子生物学 经验分享：从投稿到正式接受历时一年，经过三轮修改，每轮审稿周期都不超过一个月，最终有了好的结果。人生第一篇NC！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16c85167147, createdName=146cbb29m02暂无昵称, createdTime=Tue Sep 03 13:13:35 CST 2024, time=2024-09-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2285207, encodeId=c855228520eed, content=nature communication为什么第一个审稿人审稿一结束，就把意见发给我了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 10:45:01 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286693, encodeId=91272286693af, content=各位院士，请问nc的外审通过率有多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b49839896, createdName=ms9000001395868499, createdTime=Wed Oct 29 09:15:14 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285205, encodeId=8d28228520562, content=偏重的研究方向：缺血再灌注损伤;肠黏膜 经验分享：我目前有两个审稿人，第一个昨天完成审稿，编辑居然把第一个审稿人的意见发给我了，看邮件的意思像拒稿也像大修，审稿人的最后一句话：Taken together I cannot recommend the manuscript for publication in its present form.大家有遇到这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 09:55:05 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2224058, encodeId=2d6b22240584c, content=有大佬知道Review Complete后还要多久编辑才返回结果吗？ Stage Start Date Manuscript under consideration 22nd August 24 Review Complete 22nd August 24 All Reviewers Assigned 5th August 24 Manuscript under consideration 4th August 24 Contacting Potential Reviewers 4th August 24 Manuscript under consideration 30th July 24 Editor Assigned 30th July 24 Manuscript submitted 29th July 24 Submission in process 29th July 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a8426823, createdName=ms9000001478887667, createdTime=Wed Sep 04 17:45:14 CST 2024, time=2024-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2284421, encodeId=6812228442158, content=投稿命中率:25.0 偏重的研究方向：分子生物学;血液 经验分享：实验室同时投了两篇NC，两篇都是投大子刊被拒要求转NC的，结果大家觉得质量更高的那一篇反而被NC编辑直接拒了，另一篇技术含量低一些但带领域交叉的一篇送审修回了，直接脑子懵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b049736141, createdName=ms3000001475237117, createdTime=Sat Oct 11 17:03:48 CST 2025, time=2025-10-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1240708, encodeId=34761240e08c3, content=有从nature metabolism transfer过来NC的吗? 送审机会大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VsrhoYCAOiaTrrwt0HqSsGYQYegxVBadSem5S9wJnOugf5N8INwXDaicZTRzeAIp3Qiae0Qabf6AEQzTibZkyLrNJA/132, createdBy=9f7e2217563, createdName=good123, createdTime=Wed Aug 24 14:00:17 CST 2022, time=2022-08-24, status=1, ipAttribution=)]

2025-10-18 sunyong_97 来自湖北省

偏重的研究方向：缺血再灌注损伤;肠黏膜
经验分享：我目前有两个审稿人，第一个昨天完成审稿，编辑居然把第一个审稿人的意见发给我了，看邮件的意思像拒稿也像大修，审稿人的最后一句话：Taken together I cannot recommend the manuscript for publication in its present form.大家有遇到这种情况吗？

190 3 举报

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2228483, encodeId=842c22284832f, content=偏重的研究方向：医学;综合性期刊 经验分享：12天了，还在manuscript under consideration，编辑处理是真的慢🙃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd35613068, createdName=ms1000000741572856, createdTime=Mon Sep 30 00:24:29 CST 2024, time=2024-09-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=855, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2291254, encodeId=207222912548f, content=偏重的研究方向：医学;分子生物学 经验分享：之前投过一篇，外审两个多月杯具。11月20号又投了另一篇，11月27号muc，希望给个机会送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9349755523, createdName=ms4000002010943622, createdTime=Sun Nov 30 22:49:46 CST 2025, time=2025-11-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2223835, encodeId=c62622238351c, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：分子生物学 经验分享：从投稿到正式接受历时一年，经过三轮修改，每轮审稿周期都不超过一个月，最终有了好的结果。人生第一篇NC！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16c85167147, createdName=146cbb29m02暂无昵称, createdTime=Tue Sep 03 13:13:35 CST 2024, time=2024-09-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2285207, encodeId=c855228520eed, content=nature communication为什么第一个审稿人审稿一结束，就把意见发给我了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 10:45:01 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286693, encodeId=91272286693af, content=各位院士，请问nc的外审通过率有多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b49839896, createdName=ms9000001395868499, createdTime=Wed Oct 29 09:15:14 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285205, encodeId=8d28228520562, content=偏重的研究方向：缺血再灌注损伤;肠黏膜 经验分享：我目前有两个审稿人，第一个昨天完成审稿，编辑居然把第一个审稿人的意见发给我了，看邮件的意思像拒稿也像大修，审稿人的最后一句话：Taken together I cannot recommend the manuscript for publication in its present form.大家有遇到这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 09:55:05 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2224058, encodeId=2d6b22240584c, content=有大佬知道Review Complete后还要多久编辑才返回结果吗？ Stage Start Date Manuscript under consideration 22nd August 24 Review Complete 22nd August 24 All Reviewers Assigned 5th August 24 Manuscript under consideration 4th August 24 Contacting Potential Reviewers 4th August 24 Manuscript under consideration 30th July 24 Editor Assigned 30th July 24 Manuscript submitted 29th July 24 Submission in process 29th July 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a8426823, createdName=ms9000001478887667, createdTime=Wed Sep 04 17:45:14 CST 2024, time=2024-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2284421, encodeId=6812228442158, content=投稿命中率:25.0 偏重的研究方向：分子生物学;血液 经验分享：实验室同时投了两篇NC，两篇都是投大子刊被拒要求转NC的，结果大家觉得质量更高的那一篇反而被NC编辑直接拒了，另一篇技术含量低一些但带领域交叉的一篇送审修回了，直接脑子懵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b049736141, createdName=ms3000001475237117, createdTime=Sat Oct 11 17:03:48 CST 2025, time=2025-10-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1240708, encodeId=34761240e08c3, content=有从nature metabolism transfer过来NC的吗? 送审机会大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VsrhoYCAOiaTrrwt0HqSsGYQYegxVBadSem5S9wJnOugf5N8INwXDaicZTRzeAIp3Qiae0Qabf6AEQzTibZkyLrNJA/132, createdBy=9f7e2217563, createdName=good123, createdTime=Wed Aug 24 14:00:17 CST 2022, time=2022-08-24, status=1, ipAttribution=)]

2024-09-04 ms9000001478887667 来自湖北省

有大佬知道Review Complete后还要多久编辑才返回结果吗？
Stage Start Date
Manuscript under consideration 22nd August 24
Review Complete 22nd August 24
All Reviewers Assigned 5th August 24
Manuscript under consideration 4th August 24
Contacting Potential Reviewers 4th August 24
Manuscript under consideration 30th July 24
Editor Assigned 30th July 24
Manuscript submitted 29th July 24
Submission in process 29th July 24

418 4 举报

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2228483, encodeId=842c22284832f, content=偏重的研究方向：医学;综合性期刊 经验分享：12天了，还在manuscript under consideration，编辑处理是真的慢🙃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd35613068, createdName=ms1000000741572856, createdTime=Mon Sep 30 00:24:29 CST 2024, time=2024-09-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=855, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2291254, encodeId=207222912548f, content=偏重的研究方向：医学;分子生物学 经验分享：之前投过一篇，外审两个多月杯具。11月20号又投了另一篇，11月27号muc，希望给个机会送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9349755523, createdName=ms4000002010943622, createdTime=Sun Nov 30 22:49:46 CST 2025, time=2025-11-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2223835, encodeId=c62622238351c, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：分子生物学 经验分享：从投稿到正式接受历时一年，经过三轮修改，每轮审稿周期都不超过一个月，最终有了好的结果。人生第一篇NC！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16c85167147, createdName=146cbb29m02暂无昵称, createdTime=Tue Sep 03 13:13:35 CST 2024, time=2024-09-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2285207, encodeId=c855228520eed, content=nature communication为什么第一个审稿人审稿一结束，就把意见发给我了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 10:45:01 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286693, encodeId=91272286693af, content=各位院士，请问nc的外审通过率有多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b49839896, createdName=ms9000001395868499, createdTime=Wed Oct 29 09:15:14 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285205, encodeId=8d28228520562, content=偏重的研究方向：缺血再灌注损伤;肠黏膜 经验分享：我目前有两个审稿人，第一个昨天完成审稿，编辑居然把第一个审稿人的意见发给我了，看邮件的意思像拒稿也像大修，审稿人的最后一句话：Taken together I cannot recommend the manuscript for publication in its present form.大家有遇到这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 09:55:05 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2224058, encodeId=2d6b22240584c, content=有大佬知道Review Complete后还要多久编辑才返回结果吗？ Stage Start Date Manuscript under consideration 22nd August 24 Review Complete 22nd August 24 All Reviewers Assigned 5th August 24 Manuscript under consideration 4th August 24 Contacting Potential Reviewers 4th August 24 Manuscript under consideration 30th July 24 Editor Assigned 30th July 24 Manuscript submitted 29th July 24 Submission in process 29th July 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a8426823, createdName=ms9000001478887667, createdTime=Wed Sep 04 17:45:14 CST 2024, time=2024-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2284421, encodeId=6812228442158, content=投稿命中率:25.0 偏重的研究方向：分子生物学;血液 经验分享：实验室同时投了两篇NC，两篇都是投大子刊被拒要求转NC的，结果大家觉得质量更高的那一篇反而被NC编辑直接拒了，另一篇技术含量低一些但带领域交叉的一篇送审修回了，直接脑子懵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b049736141, createdName=ms3000001475237117, createdTime=Sat Oct 11 17:03:48 CST 2025, time=2025-10-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1240708, encodeId=34761240e08c3, content=有从nature metabolism transfer过来NC的吗? 送审机会大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VsrhoYCAOiaTrrwt0HqSsGYQYegxVBadSem5S9wJnOugf5N8INwXDaicZTRzeAIp3Qiae0Qabf6AEQzTibZkyLrNJA/132, createdBy=9f7e2217563, createdName=good123, createdTime=Wed Aug 24 14:00:17 CST 2022, time=2022-08-24, status=1, ipAttribution=)]

2025-10-11 ms3000001475237117 来自北京

投稿命中率:25.0
偏重的研究方向：分子生物学;血液
经验分享：实验室同时投了两篇NC，两篇都是投大子刊被拒要求转NC的，结果大家觉得质量更高的那一篇反而被NC编辑直接拒了，另一篇技术含量低一些但带领域交叉的一篇送审修回了，直接脑子懵

1 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2228483, encodeId=842c22284832f, content=偏重的研究方向：医学;综合性期刊 经验分享：12天了，还在manuscript under consideration，编辑处理是真的慢🙃, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=327, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6cd35613068, createdName=ms1000000741572856, createdTime=Mon Sep 30 00:24:29 CST 2024, time=2024-09-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1188722, encodeId=30b91188e22f5, content=偏重的研究方向：综合学科 经验分享：已经under consideration9天了，还有希望吗？？兄弟们？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=855, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/bS6Jiap9V4MjjfWN9KrfD7FKYQQFFLvOIibpVaUN6OF4Gw0oibQSqjh7BSxicfcFMSkDfx0Wd4V35JzQiaUYSdfcpicQ/132, createdBy=05772513004, createdName=hezhixin, createdTime=Fri Jan 28 01:42:25 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2291254, encodeId=207222912548f, content=偏重的研究方向：医学;分子生物学 经验分享：之前投过一篇，外审两个多月杯具。11月20号又投了另一篇，11月27号muc，希望给个机会送审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9349755523, createdName=ms4000002010943622, createdTime=Sun Nov 30 22:49:46 CST 2025, time=2025-11-30, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2223835, encodeId=c62622238351c, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：分子生物学 经验分享：从投稿到正式接受历时一年，经过三轮修改，每轮审稿周期都不超过一个月，最终有了好的结果。人生第一篇NC！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=637, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16c85167147, createdName=146cbb29m02暂无昵称, createdTime=Tue Sep 03 13:13:35 CST 2024, time=2024-09-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2285207, encodeId=c855228520eed, content=nature communication为什么第一个审稿人审稿一结束，就把意见发给我了呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 10:45:01 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2286693, encodeId=91272286693af, content=各位院士，请问nc的外审通过率有多少？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=199, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b49839896, createdName=ms9000001395868499, createdTime=Wed Oct 29 09:15:14 CST 2025, time=2025-10-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285205, encodeId=8d28228520562, content=偏重的研究方向：缺血再灌注损伤;肠黏膜 经验分享：我目前有两个审稿人，第一个昨天完成审稿，编辑居然把第一个审稿人的意见发给我了，看邮件的意思像拒稿也像大修，审稿人的最后一句话：Taken together I cannot recommend the manuscript for publication in its present form.大家有遇到这种情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64b1467806, createdName=sunyong_97, createdTime=Sat Oct 18 09:55:05 CST 2025, time=2025-10-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2224058, encodeId=2d6b22240584c, content=有大佬知道Review Complete后还要多久编辑才返回结果吗？ Stage Start Date Manuscript under consideration 22nd August 24 Review Complete 22nd August 24 All Reviewers Assigned 5th August 24 Manuscript under consideration 4th August 24 Contacting Potential Reviewers 4th August 24 Manuscript under consideration 30th July 24 Editor Assigned 30th July 24 Manuscript submitted 29th July 24 Submission in process 29th July 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a77a8426823, createdName=ms9000001478887667, createdTime=Wed Sep 04 17:45:14 CST 2024, time=2024-09-04, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2284421, encodeId=6812228442158, content=投稿命中率:25.0 偏重的研究方向：分子生物学;血液 经验分享：实验室同时投了两篇NC，两篇都是投大子刊被拒要求转NC的，结果大家觉得质量更高的那一篇反而被NC编辑直接拒了，另一篇技术含量低一些但带领域交叉的一篇送审修回了，直接脑子懵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b049736141, createdName=ms3000001475237117, createdTime=Sat Oct 11 17:03:48 CST 2025, time=2025-10-11, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1240708, encodeId=34761240e08c3, content=有从nature metabolism transfer过来NC的吗? 送审机会大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=506, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VsrhoYCAOiaTrrwt0HqSsGYQYegxVBadSem5S9wJnOugf5N8INwXDaicZTRzeAIp3Qiae0Qabf6AEQzTibZkyLrNJA/132, createdBy=9f7e2217563, createdName=good123, createdTime=Wed Aug 24 14:00:17 CST 2022, time=2022-08-24, status=1, ipAttribution=)]

2022-08-24 good123

有从nature metabolism transfer过来NC的吗? 送审机会大吗

506 1 举报

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务